Xilio Therapeutics (XLO) Research & Development (2020 - 2026)

Xilio Therapeutics has disclosed Research & Development across 7 years of filings, most recently posting $14.6 million for Q2 2026.

• In Q2 2026, Research & Development fell 5.03% year-over-year to $14.6 million; the TTM figure through Jun 2026 stood at $66.8 million (up 54.74% YoY), while the FY2025 annual figure was $56.0 million, up 35.98% from the prior year.
• Research & Development came in at $14.6 million for Q2 2026 at Xilio Therapeutics, down from $19.8 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $19.8 million in Q1 2026 to a low of $8.3 million in Q1 2025.
• Average Research & Development over 5 years is $13.5 million, with a median of $13.8 million recorded in 2023.
• Year-over-year, Research & Development slumped 35.53% in 2024 and jumped 139.92% in 2026.
• Over 5 years, Research & Development stood at $15.0 million in 2022, then dropped by 21.74% to $11.7 million in 2023, then fell by 24.71% to $8.8 million in 2024, then jumped by 105.09% to $18.1 million in 2025, then decreased by 19.66% to $14.6 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $14.6 million in Q2 2026, $19.8 million in Q1 2026, and $18.1 million in Q4 2025.